News | December 06, 2010

Cordis Enters Distribution Agreement for Ostial Stent Positioning System

December 6, 2010 – Cordis Corp. has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the Ostial Pro Stent Positioning System.

The Ostial Pro is the only aorto-ostial stent positioning system for coronary and peripheral applications. It is intended to optimize the treatment of patients who require a stent implantation for treatment for aorto-ostial blockages.

Aorto-ostial blockages occur at the origin of blood vessels arising from the aorta. This occurs in the right and left main coronary arteries, in coronary bypass grafts and in the renal arteries. These blockages comprise approximately 95 percent of all renal stent interventions and 8 percent of coronary stent interventions.

It is critical for the end of the stent to align precisely with the origin of the blood vessel in these cases. Using two-dimensional X-ray imaging and angiography is challenging, time-consuming and can lead to increased cost and length of procedures, as well as increased dye and radiation exposure. Imprecise positioning often requires the use of additional stents to treat the lesion and may increase risks of renarrowing.

“Ostial Pro is a simple solution to a principal challenge of aorto-ostial stent positioning by providing visual and tactile identification of the true ostium,” said Campbell Rogers, M.D., chief scientific officer and global head of research and development, Cordis. “The Ostial Pro facilitates precise stent implantation of aorto-ostial stents by identifying the true ostium. This can help make precise stent placement easier, safer and more predictable. This technology may reduce the need for additional stents and may reduce the risk of having to perform another intervention for restenosis. Based on these benefits, this simple device should become a standard element of aorto-ostial stenting.”

The stent is FDA-cleared and is currently being sold only in the United States by Ostial Solutions. Cordis plans to assume worldwide distribution in the first half of 2011.

For more information:,

Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init